Clearside Biomedical — Investor Presentation (May 2019)
37 slides from Clearside Biomedical's investor presentation, May 22, 2019
Slide 1: Corporate Presentation | May 2019
Corporate Presentation | May 2019 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”
Slide 3: Clearside Biomedical Overview
Clearside Biomedical Overview Dedicated to developing treatments that restore and preserve vision for people with serious eye diseases Novel, therapeutic platform combines patented suprachoroidal space injection technology with a proprietary drug formulation Validating platform with first potential
Slide 4: Proprietary Approach to Treating Eye Diseases
Therapeutics: Small Molecules Biologics Gene Therapy Proprietary Approach to Treating Eye Diseases Clearside Suprachoroidal Space Injection Platform Suprachoroidal Space (SCS) Device: SCS Microinjector™
Slide 5: Exclusive and Proprietary Access to the Back of the Eye
Exclusive and Proprietary Access to the Back of the Eye
Slide 6: Differences in Procedures to Reach the Back of the Eye
Differences in Procedures to Reach the Back of the Eye Suprachoroidal Space (SCS) Injection Fluid flows instantaneously and posteriorly Consistent suprachoroidal injection procedure Fluid with drug is absorbed into the choroid, retina, and retinal pigment epithelium (RPE) Intravitreal Injection Broa
Slide 7: Novel Treatment Opportunities Via the Suprachoroidal Space
Novel Treatment Opportunities Via the Suprachoroidal Space (SCS) References: 1. Rai UDJ, Young SA, Thrimawithana TR, et al. The suprachoroidal pathway: a new drug delivery route to the back of the eye. Drug Discov Today. 2015;20(4):491-495. 3. Moisseiev E, Loewenstein A, Yiu G. The suprachoroidal sp
Slide 8: Strong Intellectual Property Coverage of SCS Platform
15 Apparatus using loss-of-resistance technology Administration of any anti-inflammatory drug to the suprachoroidal space by microinjection Methods of treating macular edema or uveitis Methods using loss-of-resistance technology Apparatus having / methods using an adjustable puncture member Administ
Slide 9: Pipeline of SCS Treatments with Broad Applicability
INDICATION STUDY DRUG CURRENT STATUS Uveitis (macular edema associated with uveitis) XIPERE™ (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection DME (diabetic macular edema) XIPERE™ Wet AMD Undisclosed DME Undisclosed Inherited Retinal Diseases Gene Therapy Pipeline of SCS T
Slide 10: The Opportunity: Macular Edema Associated with Uveitis
The Opportunity No approved treatment for macular edema associated with uveitis All anatomic locations of uveitis included in Clearside clinical trials ~50% of patients continue to have macular edema, even after a course of treatment for non-infectious uveitis Macular Edema Associated with Uveitis P
Slide 11: Market Size and Current Treatment Paradigm for Uveitis
Market Size and Current Treatment Paradigm for Uveitis 350,000 patients US uveitis patients ~115,500 patients 33-47% macular edema 210,000 eyes 82% disease in both eyes Corticosteroid Drops CURRENT TREATMENTS Intravitreal triamcinolone acetonide (TA) LOCAL INJECTIONS TOPICAL Sub-tenon TA Sustained r
Slide 12: Novel Approach to Targeting Uveitic Macular Edema
Pivotal Phase 3 PEACHTREE trial met its primary endpoint NDA submitted in Q4 2018 with October 19, 2019 PDUFA date If approved, XIPERE would be the first therapy for this indication If approved, commercial launch for XIPERE anticipated in Q1 2020 Novel Approach to Targeting Uveitic Macular Edema XIP
Slide 13: Designed to Improve Ocular Distribution of Triamcinolone Acetonide
Concentration (ng/g) Time, days Designed to Improve Ocular Distribution of Triamcinolone Acetonide (TA) The anterior segment is relatively spared following suprachoroidal dosing when compared to intravitreal dosing Over 10X the amount of TA remaining in the choroid and RPE following suprachoroidal a
Slide 14: PEACHTREE: Pivotal Phase Clinical Trial in Non-Infectious Uveitis
PEACHTREE: Pivotal Phase 3 Clinical Trial for Macular Edema Associated with Non-Infectious Uveitis (NIU) 3:2 randomization of XIPERE vs. sham injection; 160 subjects total Primary endpoint at 6 months; proportion of patients gaining three lines of vision compared to sham CONTROL Week-2 Day 0 Day 0 W
Slide 15: PEACHTREE Met Its Primary Endpoint
46.9% (n=45) 15.6% (n=10) % patients gaining ≥15 ETDRS letters in BCVA from baseline Proportion of patients in each arm gaining ≥ 15 ETDRS letters in BCVA from baseline at Week 24 p<0.001 N=96 N=64 PEACHTREE Met Its Primary Endpoint ETDRS = Early Treatment Diabetic Retinopathy Study | BCVA = Best Co
Slide 16: PEACHTREE Met Its Secondary Endpoint
Mean change from baseline at week 24 in central retinal thickness (microns) 480.9 µm: active arm; 525.4 µm: control arm p<0.001 Baseline retinal thickness (microns) N=96 N=64 Intention-to-treat (ITT) PEACHTREE Met Its Secondary Endpoint Mean Change from Baseline in CST at Week 24 in Microns Source:
Slide 17: Vision Gained Rapidly and Sustained Through Week 24
Baseline ETDRS letters read 54.7: active arm; 53.5: control arm Mean change at each visit from baseline in BCVA in ETDRS letters read p<0.001 Vision Gained Rapidly and Sustained Through Week 24 Mean Change in BCVA in ETDRS Letters by Visit Source: Phase 3 PEACHTREE data BCVA = Best Corrected Visual
Slide 18: Resolved Inflammation in ~70% of Patients in PEACHTREE
% patients with scores of zero at week 24 Resolution of each of these three signs of inflammation on the SUN* scales is clinically and statistically significant In subjects with scores of 2 or greater in vitreous haze, 40.9% experienced resolution in the active arm, compared to 0% of subjects in the
Slide 19: Favorable Intraocular Pressure (IOP) Profile
IOP lowering medications were initiated in 7.3% and 9.4% subjects in the XIPERE and control arms respectively Favorable Intraocular Pressure (IOP) Profile Compared to Patients Rescued with Local Corticosteroids AE = adverse event “Elevated IOP” includes (a) increased IOP, (b) ocular hypertension, an
Slide 20: Cataract Adverse Events Were Balanced Between Arms
Percentage of Cataract Adverse Events (AEs) Were Balanced Between Arms Percentage of cataract AEs Mar-2018 | NIU program | P3, PEACHTREE, trial | Topline data
Slide 21: MAGNOLIA: Observational 24 Week Extension Trial
To be eligible for MAGNOLIA, subjects must have completed PEACHTREE and NOT have received rescue medication Primary Endpoint: Time to rescue therapy relative to Day 0 of PEACHTREE MAGNOLIA: Prospective, Non-interventional, Masked, Observational 24 week Extension Trial Day 0 Week 4 Week 8 Week 12 Wee
Slide 22: Magnolia Extension Study Demonstrates Positive Efficacy and Durability Results
Efficacy 50% of patients did not receive additional medication through week 48 Results were durable for 36 weeks after last injection of XIPERE Suprachoroidally injected XIPERE significantly improved vision (~12 letters) and macular edema (~170 microns) Safety There were no Serious AEs related to st
Slide 23: XIPERE Launch Preparations
XIPERE Launch Preparations PHYSICIANS Education materials Injection training Patient access support PATIENTS Education materials Reimbursement support services PAYERS Proactive education on uveitic macular edema as an unmet need
Slide 24: Physicians Recognize the Unmet Need and Favorable Reaction to XIPERE
Physicians Recognize the Unmet Need and Over 90% Had a Favorable Reaction to the XIPERE Profile Source: Target Ophthalmologist ATU, May 2018
Slide 25: Payers Believe XIPERE Helps Fill the Unmet Need
Payers Believe XIPERE Helps Fill the Unmet Need in Uveitic Macular Edema Payers View of UME as Unmet Need Payer Reaction to XIPERE Profile 25 Sources: Target Ophthalmologist ATU, May 2018. | Payer Research, Precision for Medicine, Aug 2018. | N=10 Medical Directors, encompassing 114M covered lives
Slide 26: Broad Applicability of SCS Injection Platform
Broad Applicability of SCS Injection Platform Small Molecules Biologics Gene Therapy 26
Slide 27: Clearside Opportunities to Leverage SCS Injection Platform
Clearside Opportunities to Leverage SCS Injection Platform Suprachoroidal Space (SCS) Injection Platform 27 Uveitic Macular Edema NDA Submitted October 19, 2019 PDUFA Date Globalization & Label Expansion Non-infectious Uveitis DME monotherapy Platform Expansion Gene Therapy Platform Expansion Small
Slide 28: Potential Label Expansion: Diabetic Macular Edema (DME)
The Opportunity Real world data demonstrates patients missing out on visual gains Patients have variable response to anti-VEGF treatment High burden for DME patients leading to poor compliance Potential Label Expansion: Diabetic Macular Edema (DME) 28 Primary Need Improved resolution of edema and lo
Slide 29: Market Size and Current Treatment Paradigm for DME
Market Size and Current Treatment Paradigm for DME 8.3M patients Diabetic Retinopathy patients in U.S. 1.1M patients DME patients 29 Anti-VEGF Sustained release steroid Intravitreal Triamcinolone Acetonide 1 2 3 2nd Line treatment 1st Line treatment CURRENT TREATMENTS
Slide 30: Treatment Burden and Patient Compliance Create Need For Options
Treatment Burden and Patient Compliance Create Need For Options XIPERE has the potential to maintain visual gains on a quarterly dosing regimen Current anti-VEGFs require retreatment every 4 to 8 weeks Subjects gained approximately 10 letters and were maintained for 12 weeks with XIPERE + intravitre
Slide 31: Potential Platform Expansion: Small Molecules and Biologics
The Opportunity Current intravitreal treatments have diffuse distribution Protection of off-target tissues Migration of small molecules into the anterior chamber Limited duration of action Potential Platform Expansion: Small Molecules and Biologics 31 Primary Need Targeted delivery to retina with pr
Slide 32: Potential Platform Expansion: Small Molecules
Potential Platform Expansion: Small Molecules SCS Platform May Offer Unique Distribution and Better Duration 32 High drug levels achieved in retina and choroid-RPE-sclera Concentration presented as mean + SEM Based on non-clinical data
Slide 33: Potential Platform Expansion: Ocular Gene Therapy
Opportunity Avoid risks of vitrectomy (surgery) Avoid risks of retinotomy, subretinal injection, and macular detachment Potential for broader retinal coverage Enhance patient access Convert gene therapy into an office-based procedure Potential Platform Expansion: Ocular Gene Therapy 33 Primary Need
Slide 34: Experienced Leadership Team
Experienced Leadership Team 34 Clearside Team Ophthalmic Experience George Lasezkay Pharm.D., J.D. | Interim CEO and Director 30 years experience Allergan, Acucela, Novagali, Amakem, RetroSense Thomas Ciulla M.D., MBA | Chief Medical Officer 27 years experience Spark Therapeutics, Ophthotech, Indian
Slide 35: Financial Summary
Financial Summary March 31, 2019 Cash, cash equivalents and short-term investments $34,938 Total assets 37,534 Long-term debt (including current portion) 10,036 Total liabilities 21,443 Total stockholders’ equity 16,091 Common shares outstanding (as of May 6, 2019) 37,595,551 ($000’s except share co
Slide 36: Clearside Biomedical: Five Key Investment Themes
Clearside Biomedical: Five Key Investment Themes Large and growing retinal market opportunity Patented technology and delivery approach Proprietary access to the suprachoroidal space Upcoming PDUFA date in Oct. 2019 for XIPERE Partnering to monetize and expand use of SCS platform 36
Slide 37: "D Sas |
"D Sas |
Clearside Biomedical — Investor Presentation (May 2019) on 6ix